



BSI Standards Publication

Medical laboratories — Requirements for quality and competence

National foreword

This British Standard is the UK implementation of EN ISO 15189:2022+A11:2023. It is derived from ISO 15189:2022. It supersedes BS EN ISO 15189:2022, which is withdrawn.

The UK participation in its preparation was entrusted to Technical Committee CH/212, IVDs.

A list of organizations represented on this committee can be obtained on request to its committee manager.

Contractual and legal considerations

This publication has been prepared in good faith, however no representation, warranty, assurance or undertaking (express or implied) is or will be made, and no responsibility or liability is or will be accepted by BSI in relation to the adequacy, accuracy, completeness or reasonableness of this publication. All and any such responsibility and liability is expressly disclaimed to the full extent permitted by the law.

This publication is provided as is, and is to be used at the recipient's own risk.

The recipient is advised to consider seeking professional guidance with respect to its use of this publication.

This publication is not intended to constitute a contract. Users are responsible for its correct application.

This publication has been prepared under a mandate given to the European Standards Organizations by the European Commission and the European Free Trade Association. It is intended to support requirements of the EU legislation detailed in the European Foreword. A European Annex, usually Annex ZA or ZZ, describes how this publication relates to that EU legislation.

For the Great Britain market (England, Scotland and Wales), if UK Government has designated this publication for conformity with UKCA marking (or similar) legislation, it may contain an additional National Annex. Where such a National Annex exists, it shows the correlation between this publication and the relevant UK legislation. If there is no National Annex of this kind, the relevant Annex ZA or ZZ in the body of the European text will indicate the relationship to UK regulation applicable in Great Britain. References to EU legislation may need to be read in accordance with the UK designation and the applicable UK law. Further information on designated standards can be found at www.bsigroup.com/standardsandregulation.

For the Northern Ireland market, UK law will continue to implement relevant EU law subject to periodic confirmation. Therefore Annex ZA/ZZ in the European text, and references to EU legislation, are still valid for this market.

UK Government is responsible for legislation. For information on legislation and policies relating to that legislation, consult the relevant pages of www.gov.uk.

© The British Standards Institution 2023
Published by BSI Standards Limited 2023

ISBN 978 0 539 29560 3

ICS 03.120.10; 11.100.01

Compliance with a British Standard cannot confer immunity from legal obligations.

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 December 2022.

Amendments/corrigenda issued since publication

Date	Text affected
31 December 2023	Implementation of CEN amendment A11:2023: Annex ZA added.

English Version

Medical laboratories - Requirements for quality and competence (ISO 15189:2022)

Laboratoires de biologie médicale - Exigences
concernant la qualité et la compétence (ISO
15189:2022)

Medizinische Laboratorien - Anforderungen an die
Qualität und Kompetenz (ISO 15189:2022)

This European Standard was approved by CEN on 15 November 2022.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

European foreword

This document (EN ISO 15189:2022) has been prepared by Technical Committee ISO/TC 212 "Clinical laboratory testing and in vitro diagnostic test systems" in collaboration with Technical Committee CEN/TC 140 "In vitro diagnostic medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by June 2023, and conflicting national standards shall be withdrawn at the latest by December 2025.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 15189:2012 and EN ISO 22870:2016.

This document has been prepared under a Standardization Request given to CEN by the European Commission and the European Free Trade Association.

Any feedback and questions on this document should be directed to the users' national standards body/national committee. A complete listing of these bodies can be found on the CEN website.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Türkiye and the United Kingdom.

Endorsement notice

The text of ISO 15189:2022 has been approved by CEN as EN ISO 15189:2022 without any modification.

European foreword to amendment A11

This document (EN ISO 15189:2022/A11:2023) has been prepared by Technical Committee CEN/TC 140 “In vitro diagnostic medical devices” the secretariat of which is held by DIN.

This Amendment to the European Standard EN ISO 15189:2022 shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by May 2024, and conflicting national standards shall be withdrawn at the latest by November 2026.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document has been prepared under a Standardization Request given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s) / Regulation(s).

For the relationship with EU Directive(s) / Regulation(s), see informative Annex ZA, which is an integral part of this document.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Annex ZA (informative)

Relationship between this European Standard and the requirements of Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and repealing Regulation (EEC) No 339/93 aimed to be covered

This European Standard has been prepared under Commission Implementing Decision C(2021)9277 of 17.12.2021 on a standardisation request to the European Committee for Standardisation and the European Committee for Electrotechnical Standardisation as regards accreditation and conformity assessment in support of Regulation (EC) No 765/2008 of the European Parliament and of the Council (M/580), to provide one voluntary means of conforming to Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and repealing Regulation (EEC) No 339/93 [OJ L 218].

Once this standard is cited in the Official Journal of the European Union under that Regulation, compliance with the normative clauses of this standard given in Table Z confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding requirements of that Regulation, and associated EFTA regulations.

Table ZA.1 — Correspondence between this European Standard and Regulation (EC) No 765/2008 of the European Parliament and of the Council of 9 July 2008 setting out the requirements for accreditation and repealing Regulation (EEC) No 339/93 [OJ L 218]

Requirement of Regulation (EC) 765/2008	Clause(s)/sub-clause(s) of this EN	Remarks/Notes
Article 8(10)	4 General requirements 5 Structural requirements 6 Resource requirements 7 Process requirements 8 Management system requirements	In addition to the accreditation of laboratories in line with Article 5(5)(c) of Regulation (EU) 2017/746

WARNING 1 — Presumption of conformity stays valid only as long as a reference to this European Standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2 — Other Union legislation may be applicable to the product(s) falling within the scope of this standard.

Contents

Page

Foreword	vi
Introduction	vii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 General requirements	8
4.1 Impartiality	8
4.2 Confidentiality	8
4.2.1 Management of information	8
4.2.2 Release of information	9
4.2.3 Personnel responsibility	9
4.3 Requirements regarding patients	9
5 Structural and governance requirements	9
5.1 Legal entity	9
5.2 Laboratory director	10
5.2.1 Laboratory director competence	10
5.2.2 Laboratory director responsibilities	10
5.2.3 Delegation of duties	10
5.3 Laboratory activities	10
5.3.1 General	10
5.3.2 Conformance with requirements	10
5.3.3 Advisory activities	10
5.4 Structure and authority	11
5.4.1 General	11
5.4.2 Quality management	11
5.5 Objectives and policies	11
5.6 Risk management	12
6 Resource requirements	12
6.1 General	12
6.2 Personnel	12
6.2.1 General	12
6.2.2 Competence requirements	12
6.2.3 Authorization	13
6.2.4 Continuing education and professional development	13
6.2.5 Personnel records	13
6.3 Facilities and environmental conditions	13
6.3.1 General	13
6.3.2 Facility controls	14
6.3.3 Storage facilities	14
6.3.4 Personnel facilities	14
6.3.5 Sample collection facilities	14
6.4 Equipment	15
6.4.1 General	15
6.4.2 Equipment requirements	15
6.4.3 Equipment acceptance procedure	15
6.4.4 Equipment instructions for use	15
6.4.5 Equipment maintenance and repair	15
6.4.6 Equipment adverse incident reporting	16
6.4.7 Equipment records	16
6.5 Equipment calibration and metrological traceability	17
6.5.1 General	17
6.5.2 Equipment calibration	17

6.5.3	Metrological traceability of measurement results	17
6.6	Reagents and consumables	18
6.6.1	General	18
6.6.2	Reagents and consumables — Receipt and storage	18
6.6.3	Reagents and consumables — Acceptance testing	18
6.6.4	Reagents and consumables — Inventory management	18
6.6.5	Reagents and consumables — Instructions for use	19
6.6.6	Reagents and consumables — Adverse incident reporting	19
6.6.7	Reagents and consumables — Records	19
6.7	Service agreements	19
6.7.1	Agreements with laboratory users	19
6.7.2	Agreements with POCT operators	19
6.8	Externally provided products and services	20
6.8.1	General	20
6.8.2	Referral laboratories and consultants	20
6.8.3	Review and approval of externally provided products and services	20
7	Process requirements	21
7.1	General	21
7.2	Pre-examination processes	21
7.2.1	General	21
7.2.2	Laboratory information for patients and users	21
7.2.3	Requests for providing laboratory examinations	21
7.2.4	Primary sample collection and handling	22
7.2.5	Sample transportation	23
7.2.6	Sample receipt	24
7.2.7	Pre-examination handling, preparation, and storage	24
7.3	Examination processes	25
7.3.1	General	25
7.3.2	Verification of examination methods	25
7.3.3	Validation of examination methods	25
7.3.4	Evaluation of measurement uncertainty (MU)	26
7.3.5	Biological reference intervals and clinical decision limits	26
7.3.6	Documentation of examination procedures	27
7.3.7	Ensuring the validity of examination results	27
7.4	Post-examination processes	30
7.4.1	Reporting of results	30
7.4.2	Post-examination handling of samples	32
7.5	Nonconforming work	33
7.6	Control of data and information management	33
7.6.1	General	33
7.6.2	Authorities and responsibilities for information management	33
7.6.3	Information systems management	34
7.6.4	Downtime plans	34
7.6.5	Off site management	34
7.7	Complaints	34
7.7.1	Process	34
7.7.2	Receipt of complaint	35
7.7.3	Resolution of complaint	35
7.8	Continuity and emergency preparedness planning	35
8	Management system requirements	35
8.1	General requirements	35
8.1.1	General	35
8.1.2	Fulfilment of management system requirements	36
8.1.3	Management system awareness	36
8.2	Management system documentation	36
8.2.1	General	36
8.2.2	Competence and quality	36

8.2.3	Evidence of commitment.....	36
8.2.4	Documentation.....	36
8.2.5	Personnel access.....	36
8.3	Control of management system documents.....	37
8.3.1	General.....	37
8.3.2	Control of documents.....	37
8.4	Control of records.....	37
8.4.1	Creation of records.....	37
8.4.2	Amendment of records.....	37
8.4.3	Retention of records.....	38
8.5	Actions to address risks and opportunities for improvement.....	38
8.5.1	Identification of risks and opportunities for improvement.....	38
8.5.2	Acting on risks and opportunities for improvement.....	38
8.6	Improvement.....	39
8.6.1	Continual improvement.....	39
8.6.2	Laboratory patients, user, and personnel feedback.....	39
8.7	Nonconformities and corrective actions.....	39
8.7.1	Actions when nonconformity occurs.....	39
8.7.2	Corrective action effectiveness.....	40
8.7.3	Records of nonconformities and corrective actions.....	40
8.8	Evaluations.....	40
8.8.1	General.....	40
8.8.2	Quality indicators.....	40
8.8.3	Internal audits.....	40
8.9	Management reviews.....	41
8.9.1	General.....	41
8.9.2	Review input.....	41
8.9.3	Review output.....	41
Annex A (normative) Additional requirements for Point-of-Care Testing (POCT).....		43
Annex B (informative) Comparison between ISO 9001:2015 and ISO 15189:2022 (this document).....		44
Annex C (informative) Comparison between ISO 15189:2012 and ISO 15189:2022 (this document).....		54
Bibliography.....		61

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 140, *In vitro diagnostic medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This fourth edition cancels and replaces the third edition (ISO 15189:2012), which has been technically revised. It also replaces ISO 22870:2016.

The main changes are as follows:

- Alignment with ISO/IEC 17025:2017 resulted in the management requirements now appearing at the end of the document;
- Requirements for point-of-care testing (POCT), previously in ISO 22870, have been incorporated;
- Increased emphasis on risk management.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

The objective of this document is to promote the welfare of patients and satisfaction of laboratory users through confidence in the quality and competence of medical laboratories.

This document contains requirements for the medical laboratory to plan and implement actions to address risks and opportunities for improvement. Benefits of this approach include: increasing the effectiveness of the management system, decreasing probability of invalid results, and reducing potential harm to patients, laboratory personnel, the public and the environment.

The requirements for risk management are aligned with the principles of ISO 22367.

The requirements for laboratory safety are aligned with the principles of ISO 15190.

The requirements for sample collection and transport are aligned with ISO 20658.¹⁾

This document contains the requirements for point-of-care testing (POCT) and supersedes ISO 22870, which will be withdrawn upon publication of this document.

The format of this document is based on ISO/IEC 17025:2017.

The medical laboratory is essential to patient care; activities are provided within an ethical and governance framework, that recognizes the obligations of healthcare providers to the patient. These activities are undertaken in a timely manner to meet the needs of all patients and the personnel responsible for the care of those patients. Activities include arrangements for examination requests, patient preparation, patient identification, collection of samples, transportation, processing of patient samples, selection of examinations that are fit for intended use, examination of samples, sample storage, as well as subsequent interpretation, result reporting and advice to laboratory users. This may also include the provision of results to the patient, arrangements for urgent testing and the notification of critical results.

While this document is intended for use throughout the currently recognized medical laboratory disciplines, it can effectively be applied to other healthcare services, such as diagnostic imaging, respiratory therapy, physiological sciences, blood banks and transfusion services.

The use of this document facilitates cooperation between medical laboratories and other healthcare services, assists in the exchange of information, and in the harmonization of methods and procedures.

The comparability of patient examination results between medical laboratories, regardless of city or country, is facilitated when medical laboratories conform to this document.

When a laboratory seeks accreditation, it should select an accreditation body which operates in accordance with ISO/IEC 17011, and which takes into account the particular requirements of medical laboratories.

Comparisons between this document, ISO 9001:2015 and ISO/IEC 17025:2017 are in [Annex B](#). The comparison of ISO 15189:2012 to ISO 15189:2022 (this document) is in [Annex C](#).

1) First edition under preparation (previous edition was a Technical Specification). Stage at the time of publication: ISO/DIS 20658:2022.

Medical laboratories — Requirements for quality and competence

1 Scope

This document specifies requirements for quality and competence in medical laboratories.

This document is applicable to medical laboratories in developing their management systems and assessing their competence. It is also applicable for confirming or recognizing the competence of medical laboratories by laboratory users, regulatory authorities and accreditation bodies.

This document is also applicable to point-of-care testing (POCT).

NOTE International, national, or regional regulations or requirements can also apply to specific topics covered in this document.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO/IEC Guide 99:2007, *International vocabulary of metrology — Basic and general concepts and associated terms (VIM)*

NOTE ISO/IEC Guide 99 is also known as the Joint Committee for Guides in Metrology (JCGM) 200.

ISO/IEC 17000:2020, *Conformity assessment — Vocabulary and general principles*

ISO/IEC 17025:2017, *General requirements for the competence of testing and calibration laboratories*

3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO/IEC Guide 99 and ISO/IEC 17000 and the following apply.

ISO and IEC maintain terminology databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <https://www.electropedia.org/>

3.1

bias

measurement bias

estimate of a systematic measurement error

Note 1 to entry: This definition only applies to quantitative measurements

[SOURCE: ISO/IEC Guide 99:2007, 2.18, modified — Note 1 to entry has been added.]

3.2 biological reference interval reference interval

specified interval of the distribution of values taken from a biological reference population

Note 1 to entry: A reference interval is commonly defined as the central 95% interval. Another size or an asymmetrical location of the reference interval could be more appropriate in particular cases.

Note 2 to entry: A reference interval can depend upon the type of *primary sample* (3.25) and the *examination procedure* (3.9) used.

Note 3 to entry: In some cases, only one biological reference limit is important, usually an upper limit, "x", so that the corresponding biological reference interval would be less than or equal to "x".

Note 4 to entry: Terms such as 'normal range', 'normal values', and 'clinical range' are ambiguous and therefore discouraged.

[SOURCE: ISO 18113-1:2022, 3.1.9, modified — The EXAMPLE has been removed.]

3.3 clinical decision limit

examination (3.8) result that indicates a higher risk of adverse clinical outcomes, or is diagnostic for the presence of a specific disease

Note 1 to entry: Clinical decision limits for therapeutic drugs are called "therapeutic range".

Note 2 to entry: It is used to determine risk of disease, to diagnose or to treat.

3.4 commutability of a reference material commutability

property of a reference material, demonstrated by the closeness of agreement between the relation among the measurement results for a stated quantity in this material, obtained according to two given measurement procedures and the relation obtained among the measurement results for other specified materials

Note 1 to entry: The reference material in question is usually a calibrator and the other specified materials are usually routine samples.

Note 2 to entry: It is typical that there are more than two measurement procedures available and comparison among all applicable measurement procedures is desirable.

Note 3 to entry: Closeness of agreement of measurement results is defined in terms of fitness for purpose as appropriate for the intended use of the reference material.

Note 4 to entry: A commutability statement is restricted to the measurement procedures as specified in a particular comparison.

[SOURCE: ISO 17511:2020 3.10, modified — Note 2 to entry has been replaced by a new Note 2 to entry.]

3.5 competence

demonstrated ability to apply knowledge and skills to achieve intended results

[SOURCE: ISO/IEC 17021-1:2015, 3.7, modified — "demonstrated" added to the beginning of the definition.]

3.6**complaint**

expression of dissatisfaction by any person or organization to a *laboratory* (3.20), relating to the activities or results of that laboratory, where a response is expected

[SOURCE: ISO/IEC 17000:2020, 8.7, modified — The words “other than appeal” have been deleted, and the words “a conformity assessment body or accreditation body, relating to the activities of that body” have been replaced by “a laboratory, relating to the activities or results of that laboratory”.]

3.7**consultant**

person who provides expert advice professionally

3.8**examination**

set of operations having the objective of determining the numerical value, text value or characteristics of a property

Note 1 to entry: An examination may be the total of a number of activities, observations or measurements required to determine a value or characteristic.

Note 2 to entry: Laboratory examinations that determine a numerical value of a property are called “quantitative examinations”; those that determine the characteristics of a property are called “qualitative examinations”.

Note 3 to entry: Laboratory examinations are also called “assays” or “tests”.

3.9**examination procedure**

specifically described set of operations used in the performance of an *examination* (3.8) according to a given method

Note 1 to entry: In the IVD medical device industry and in many laboratories that use IVD medical devices, an examination procedure for an analyte in a biological sample is commonly referred to as an analytical method, analytical procedure or test procedure.

[SOURCE: ISO 15198:2004, 3.7, modified — “set of operations described specifically” changed to “specifically described set of operations”.]

3.10**external quality assessment****EQA**

evaluation of participant performance against pre-established criteria by means of interlaboratory comparisons

Note 1 to entry: Also known as proficiency testing (PT)

[SOURCE: ISO/IEC 17043:2010, 3.7 modified — The term “external quality assessment”, which was given in Note 2 to entry, is used as the main term. Notes to entry 1 and 2 have been omitted and a new Note 1 to entry added.]

3.11**impartiality**

objectivity with regard to the outcome of tasks performed by the *medical laboratory* (3.20)

Note 1 to entry: Objectivity can be understood as freedom from bias or freedom from conflicts of interest.

Note 2 to entry: Other terms that are useful in conveying the element of impartiality include “independence”, “lack of prejudice”, “neutrality”, “fairness”, “open-mindedness”, “even-handedness”, “detachment”, “balance”.

[SOURCE: ISO/IEC 17000:2020 5.3 modified — “outcome of a conformity assessment activity” has been changed to “tasks performed by the medical laboratory”. Note 2 to entry has been added.]

3.12

interlaboratory comparison

organization, performance and evaluation of measurements or *examinations* (3.8) on the same or similar materials by two or more independent laboratories in accordance with pre-determined conditions

[SOURCE: ISO/IEC 17043:2010 3.4, modified — "tests" has been replaced by "examinations". "items" has been replaced by "materials". "laboratories" has been replaced by "independent laboratories".]

3.13

internal quality control

IQC

quality control

QC

internal procedure which monitors the testing process to verify the system is working correctly and gives confidence that the results are reliable enough to be released

[SOURCE: ISO/TS 22583:2019 3.9, modified — "decide" has been replaced by "verify". Note 1 to entry has been removed.]

3.14

in vitro diagnostic medical device

IVD medical device

device, whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes and including reagents, calibrators, control materials, specimen receptacles, software, and related instruments or apparatus or other articles

[SOURCE: ISO 18113-1:2022, 3.1.33, modified — "medical" has been removed from the beginning of the definition. "and including reagents, calibrators, control materials, specimen receptacles, software, and related instruments or apparatus or other articles" has been added to the end of the definition. Notes 1 and 2 to entry have been removed.]

3.15

laboratory management

person(s) with responsibility for, and authority over a *laboratory* (3.20)

Note 1 to entry: Laboratory management has the power to delegate authority and provide resources within the laboratory.

Note 2 to entry: The laboratory management includes the laboratory director(s) and delegates together with individuals specifically assigned to ensure the quality of the activities of the laboratory.

3.16

laboratory user

individual or entity requesting services of the *medical laboratory* (3.20)

Note 1 to entry: Users can include patients, clinicians, and, other laboratories or institutions that send samples for examination.

3.17

management system

set of interrelated or interacting elements of an organization to establish policies and objectives, and processes to achieve those objectives

Note 1 to entry: This was formerly referred to and is synonymous with "quality management system".

Note 2 to entry: The management system elements establish the organization's structure, roles and responsibilities, planning, operation, policies, practices, rules, beliefs, objectives, and processes to achieve those objectives.

[SOURCE: ISO 9000:2015, 3.5.3 modified — Notes to entry 1, 3 and 4 have been removed and a new Note 1 to entry has been added.]

3.18**measurement accuracy**
accuracy of measurement
accuracy

closeness of agreement between a measured quantity value and a true quantity value of a measurand

Note 1 to entry: The concept 'measurement accuracy' is not a quantity and is not given a numerical quantity value. A measurement is said to be more accurate when it offers a smaller measurement error.

Note 2 to entry: The term "measurement accuracy" should not be used for measurement trueness and the term measurement precision should not be used for 'measurement accuracy', which, however, is related to both these concepts.

Note 3 to entry: 'Measurement accuracy' is sometimes understood as closeness of agreement between measured quantity values that are being attributed to the measurand.

[SOURCE: ISO/IEC Guide 99:2007, 2.13]

3.19**measurement uncertainty**
MU

non-negative parameter characterizing the dispersion of the quantity values being attributed to a measurand, based on the information used

Note 1 to entry: MU includes components arising from systematic effects, as in the case of corrections to the assigned quantity values of measurement standards. Sometimes estimated systematic effects are not corrected for, but instead, the associated MU components are incorporated.

Note 2 to entry: The parameter may be, for example, a standard deviation (SD) called standard MU (or a specified multiple of it), or the half-width of an interval, having a stated coverage probability.

Note 3 to entry: MU comprises, in general, of many components. Some of these may be evaluated by Type A evaluation of MU from the statistical distribution of the quantity values from series of measurements and can be characterized by SD. The other components, which may be evaluated by Type B evaluation of MU, can also be characterized by SD or evaluated from probability density functions based on experience or other information.

Note 4 to entry: In general, for a given set of information, it is understood that the MU is associated with a stated quantity value attributed to the measurand. A modification of this value may result in a modification of the associated uncertainty.

Note 5 to entry: All measurements have *bias* (3.1) and imprecision. For example, replicate measurements of a sample performed under repeatability conditions generally produce different values for the same measurand. Because the different values could all be reasonably attributed to the same amount of measurand, there is uncertainty as to which value should be reported as the value of the measurand.

Note 6 to entry: Based on available data about the analytical performance of a given measurement procedure, an estimation of MU provides an interval of values that is believed to include the actual value of the measurand, with a stated level of confidence.

Note 7 to entry: Available data about the analytical performance of a given measurement procedure typically comprise uncertainty of calibrator assigned values and long-term imprecision of IQC materials.

Note 8 to entry: In medical laboratories, most measurements are performed in singleton, and are taken to be an acceptable estimate of the value of the measurand, while the MU interval indicates other results that are also possible.

[SOURCE: ISO/IEC Guide 99:2007 2.26, modified — Notes to entry 5 to 8 have been added from ISO/TS 20914:2019 3.26.]

3.20 medical laboratory laboratory

entity for the *examination* (3.8) of materials derived from the human body for the purpose of providing information for the diagnosis, monitoring, management, prevention and treatment of disease, or assessment of health

Note 1 to entry: The laboratory can also provide advice covering all aspects of examinations including appropriate selection, the interpretation of results and advice on further examinations.

Note 2 to entry: Laboratory activities include *pre-examination* (3.24), *examination* (3.8) and *post-examination processes* (3.23).

Note 3 to entry: Materials for *examination* (3.8) include but are not limited to, microbiological, immunological, biochemical, immunohaematological, haematological, biophysical, cytological, tissue and cells, and genetic material.

3.21 patient

person who is the source of material for an *examination* (3.8)

3.22 point-of-care testing POCT

examination (3.8) performed near or at the site of a *patient* (3.21)

[SOURCE: ISO/TS 22583:2019, 3.11]

3.23 post-examination processes

processes following the *examination* (3.8) including review of results, formatting, releasing, reporting and retention of examination results, retention and storage of clinical material, *sample* (3.28) and waste disposal

3.24 pre-examination processes

processes that start, in chronological order, from the user's request and include the *examination* (3.8) request, preparation and identification of the *patient* (3.21), collection of the *primary sample(s)* (3.25), transportation to and within the *laboratory* (3.20), ending when the *examination* (3.8) begins

3.25 primary sample specimen

discrete portion of a body fluid or tissue or other sample associated with the human body taken for *examination* (3.8), study or analysis of one or more quantities or characteristics to determine the character of the whole

Note 1 to entry: The International Medical Device Regulators Forum (IMDRF) uses the term specimen in its harmonized guidance documents to mean a sample of biological origin intended for examination by a *medical laboratory* (3.20).

[SOURCE: ISO 18113-1:2022, 3.1.65, modified — Note 1 to entry has been modified. Note 2 to entry has been deleted.]

3.26 quality indicator

measure of the degree to which a large number of characteristics of an object fulfils requirements

Note 1 to entry: Measure can be expressed, for example, as % yield (% within specified requirements), % defects (% outside specified requirements), defects per million occasions (DPMO) or on the Six Sigma scale.

Note 2 to entry: Quality indicators can measure how well an organization meets the needs and requirements of users and the quality of all operational processes.

3.27

referral laboratory

external *laboratory* (3.20) to which a sample or data is submitted for *examination* (3.8)

Note 1 to entry: A referral laboratory is one to which laboratory management chooses to submit a sample or sub-sample for examination, data for analysis or interpretation, or when routine examinations cannot be carried out.

Note 2 to entry: This differs from a laboratory to which submission of samples is required by regulation, or a so called reference laboratory, e.g. public health, forensic, tumour registry, or a central (parent) facility to which submission of samples is required by structure.

3.28

sample

one or more parts taken from a *primary sample* (3.25)

3.29

trueness

measurement trueness

closeness of agreement between the average of an infinite number of replicate measured quantity values and a reference quantity value

Note 1 to entry: Measurement trueness is not a quantity and thus cannot be expressed numerically, but measures for closeness of agreement are given in ISO 5725-1.

Note 2 to entry: Measurement trueness is inversely related to systematic measurement error, but is not related to random measurement error.

Note 3 to entry: ‘Measurement accuracy’ should not be used for ‘measurement trueness’.

Note 4 to entry: For qualitative examinations, trueness of measurement (closeness of agreement) can be expressed in terms of concordance (i.e. percent agreement with a reference examination).

Note 5 to entry: Trueness is a property of the *examination procedure* (3.9) that reflects the *bias* (3.1) of the measurements from the expected or target value. It is described qualitatively as good or bad. An *examination procedure* (3.9) has good trueness if the *bias* (3.1) of the measurements is acceptable.

[SOURCE: ISO/IEC Guide 99:2007, 2.14, modified — Notes to entry 4 and 5 have been added.]

3.30

turnaround time

elapsed time between two specified points through *pre-examination* (3.24), *examination* (3.8), and *post-examination processes* (3.23)

3.31

validation

confirmation of plausibility for a specific intended use or application through the provision of objective evidence that specified requirements have been fulfilled

Note 1 to entry: Objective evidence can be obtained through observation, measurement, examination or by other means.

Note 2 to entry: The word “validated” is used to designate the corresponding status.

Note 3 to entry: Specified requirements of an examination method may include the following performance specifications: measurement trueness, measurement precision including measurement repeatability, and measurement intermediate precision, analytical specificity, including interfering substances, detection limit and quantitation limit, measuring interval, clinical relevance, diagnostic specificity and diagnostic sensitivity.

[SOURCE: ISO/IEC 17000:2020, 6.5, modified — Notes 1 to 3 to entry have been added.]

3.32 verification

confirmation of truthfulness, through the provision of objective evidence that specified requirements have been fulfilled

EXAMPLE 1 Confirmation that performance specifications of a measuring system are achieved.

EXAMPLE 2 Confirmation that a target measurement uncertainty can be met.

Note 1 to entry: Verification is the process by which the laboratory confirms that the established performance claims of a measuring system, e.g. trueness, precision, reportable range, can be replicated in the laboratory before human sample examination is performed.

Note 2 to entry: The objective evidence needed for a verification can be the results of an inspection, or other forms of determination, such as performing alternative calculations or reviewing documents.

Note 3 to entry: Verification may be sufficient to implement a new IVD device under circumstances where the *examination* (3.8) is performed and used in the manner as directed in the package insert.

Note 4 to entry: The word “verified” is used to designate the corresponding status.

[SOURCE: ISO/IEC 17000:2020, 6.6 modified — EXAMPLES 1 and 2 have been added. Notes to entry 1 to 4 have been added.]

4 General requirements

4.1 Impartiality

- a) Laboratory activities shall be undertaken impartially. The laboratory shall be structured and managed to safeguard impartiality.
- b) The laboratory management shall be committed to impartiality.
- c) The laboratory shall be responsible for the impartiality of its laboratory activities and shall not allow commercial, financial or other pressures to compromise impartiality.
- d) The laboratory shall monitor its activities and its relationships to identify threats to its impartiality. This monitoring shall include relationships of its personnel.

NOTE A relationship that threatens the impartiality of the laboratory can be based on ownership, governance, management, personnel, shared resources, finances, contracts, marketing (including branding), and payment of a sales commission or other inducement for the referral of new laboratory users, etc. Such relationships do not necessarily present the laboratory with a threat to impartiality.

- e) If a threat to impartiality is identified, the effect shall be eliminated or minimized so that the impartiality is not compromised. The laboratory shall be able to demonstrate how it mitigates such threat.

4.2 Confidentiality

4.2.1 Management of information

The laboratory shall be responsible, through legally enforceable agreements, for the management of all patient information obtained or created during the performance of laboratory activities. Management of patient information shall include privacy and confidentiality. The laboratory shall inform the user and/or the patient in advance, of the information it intends to place in the public domain. Except for information that the user and/or the patient makes publicly available, or when agreed between the laboratory and the patient (e.g. for the purpose of responding to complaints), all other information is considered proprietary information and shall be regarded as confidential.

4.2.2 Release of information

When the laboratory is required by law or authorized by contractual arrangements to release confidential information, the patient concerned shall be notified of the information released, unless prohibited by law.

Information about the patient from a source other than the patient (e.g. complainant, regulator) shall be kept confidential by the laboratory. The identity of the source shall be kept confidential by the laboratory and shall not be shared with the patient, unless agreed by the source.

4.2.3 Personnel responsibility

Personnel, including any committee members, contractors, personnel of external bodies, or individuals with access to laboratory information acting on the laboratory's behalf, shall keep confidential all information obtained or created during the performance of laboratory activities.

4.3 Requirements regarding patients

Laboratory management shall ensure that patients' well-being, safety and rights are the primary considerations. The laboratory shall establish and implement the following processes:

- a) opportunities for patients and laboratory users to provide helpful information to aid the laboratory in the selection of the examination methods, and the interpretation of the examination results;
- b) provision of patients and users with publicly available information about the examination process, including costs when applicable, and when to expect results;
- c) periodic review of the examinations offered by the laboratory to ensure they are clinically appropriate and necessary;
- d) where appropriate, disclosure to patients, users and any other relevant persons, of incidents that resulted or could have resulted in patient harm, and records of actions taken to mitigate those harms;
- e) treatment of patients, samples, or remains, with due care and respect;
- f) obtaining informed consent when required;
- g) ensuring the ongoing availability and integrity of retained patient samples and records in the event of the closure, acquisition or merger of the laboratory;
- h) making relevant information available to a patient and any other health service provider at the request of the patient or the request of a healthcare provider acting on their behalf;
- i) upholding the rights of patients to care that is free from discrimination.

5 Structural and governance requirements

5.1 Legal entity

The laboratory or the organization of which the laboratory is a part shall be an entity that can be held legally responsible for its activities.

NOTE For the purposes of this document, a government laboratory is deemed to be a legal entity on the basis of its government status.

5.2 Laboratory director

5.2.1 Laboratory director competence

The laboratory shall be directed by a person, or persons however named, with the specified qualifications, competence, delegated authority, responsibility, and resources to fulfil the requirements of this document.

5.2.2 Laboratory director responsibilities

The laboratory director is responsible for the implementation of the management system, including the application of risk management to all aspects of the laboratory operations so that risks to patient care and opportunities to improve are systematically identified and addressed.

The duties and responsibilities of the laboratory director shall be documented.

5.2.3 Delegation of duties

The laboratory director may delegate either selected duties or responsibilities, or both, to qualified and competent personnel and such delegation shall be documented. However, the laboratory director shall maintain the ultimate responsibility for the overall operation of the laboratory.

5.3 Laboratory activities

5.3.1 General

The laboratory shall specify and document the range of laboratory activities, including laboratory activities performed at sites other than the main location (e.g. POCT, sample collection) for which it conforms with this document. The laboratory shall only claim conformity with this document for this range of laboratory activities, which excludes externally provided laboratory activities on an ongoing basis.

5.3.2 Conformance with requirements

Laboratory activities shall be carried out in such a way as to meet the requirements of this document, the users, regulatory authorities and organizations providing recognition. This applies to the complete range of specified and documented laboratory activities, regardless of where the service is provided.

5.3.3 Advisory activities

Laboratory management shall ensure that appropriate laboratory advice and interpretation are available and meet the needs of patients and users.

The laboratory shall establish arrangements for communicating with laboratory users on the following when applicable:

- a) advising on choice and use of examinations, including required type of sample, clinical indications and limitations of examination methods; and the frequency of requesting the examination;
- b) providing professional judgments on the interpretation of the results of examinations;
- c) promoting the effective utilization of laboratory examinations;
- d) advising on scientific and logistical matters such as instances of failure of sample(s) to meet acceptability criteria.